R&D News | pharmaphorum

News

Beckley Canopy Therapeutics raises £7.4m for cannabis R&D

Oxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the treatment of pain and to help tackle

News

GBT heads to FDA with sickle cell drug voxelotor

Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of sickle cell disease drug voxelotor as part of a filing for accelerated approval.

News

GSK enters PARP space with TESARO acquisition

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib).

News

P&G completes acquisition of Merck KGaA’s OTC division

Procter & Gamble (P&G) has completed its acquisition of Merck KGaA’s Consumer Health business, in a move it hopes will help boost its flagging sales prospects.

News

AbbVie, Pfizer reach licencing agreement for biosimilar Humi...

AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting Pfizer’s patent dispute and allowing AbbVie

News

Celgene scores at ASH18 with double luspatercept data

A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019.

Beckley Canopy Therapeutics raises £7.4m for cannabis R&D

GBT heads to FDA with sickle cell drug voxelotor

GSK enters PARP space with TESARO acquisition

P&G completes acquisition of Merck KGaA’s OTC division

AbbVie, Pfizer reach licencing agreement for biosimilar Humi...

Celgene scores at ASH18 with double luspatercept data

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks